As healthcare leaders face the growing demand for patient-centered care (PCC), the juggling act of improving patient satisfaction, controlling costs, and driving innovation can be overwhelming.
MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback